Similar to changes in GUCY2C+ pathological brain regions, GUCY2C is overexpressed in over 95% of colorectal tumors, as well as in a subset of pancreatic, gastric, and esophageal tumors76, and is currently under investigation as a potential therapeutic target for treating GI cancers77. This evidence concerns the gene GUCY2C and colorectal neoplasm.